Treatment of polycythemia vera with imatinib mesylate

Richard T. Silver, Michael H. Bourla, Katherine Vandris, Steven Fruchtman, Jerry L. Spivak, Eric J. Feldman, August J. Salvado

Research output: Contribution to journalArticlepeer-review

Abstract

We treated 37 patients with polycythemia vera with imatinib mesylate (IM). The overall response rate was 49%. Thirty percent had a complete response, and 19%, a partial response. Thirty-one patients were treated for >120. days. Frequent side effects included nausea, diarrhea, edema, and skin rash. Whereas IM was effective in controlling erythropoiesis and reducing spleen size it was ineffective in controlling thrombocytosis. Normocellular marrow developed in 4 patients who had a complete response. Progression to overt myelofibrosis occurred in 3. Nevertheless, 6 patients have had a sustained complete response while on IM for >6. years. These patients were young, had high phlebotomy requirements, and only slightly elevated platelet counts. Therefore, we believe there may be a role for IM in patients with these characteristics whose disease cannot be controlled by, or as an alternative to, other myelosuppressive treatments.

Original languageEnglish (US)
Pages (from-to)156-162
Number of pages7
JournalLeukemia Research
Volume36
Issue number2
DOIs
StatePublished - Feb 2012

Keywords

  • Imatinib mesylate
  • Myeloproliferative disorder
  • Myeloproliferative neoplasm
  • Myelosuppresive therapy
  • Polycythemia vera
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Treatment of polycythemia vera with imatinib mesylate'. Together they form a unique fingerprint.

Cite this